title: Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction.
authors.affiliation: CLP Santé, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Lilliu
authors.forename: C
authors.initials: C
authors.lastname: Brun
authors.forename: C
authors.initials: C
authors.lastname: Le Pen
authors.forename: M
authors.initials: M
authors.lastname: Büchler
authors.forename: A
authors.initials: A
authors.lastname: Al Najjar
authors.forename: O
authors.initials: O
authors.lastname: Reigneau
authors.forename: Y
authors.initials: Y
authors.lastname: Lebranchu
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000191:economics / Q000627:therapeutic use*; D000077552:Basiliximab; D003363:Cost Control; D016572:Cyclosporine / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005602:France; D006760:Hospitalization / Q000191:economics; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D011183:Postoperative Complications / Q000191:economics / Q000453:epidemiology; D011993:Recombinant Fusion Proteins
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab